The EGFR activity of 1 is unlikely to significantly contribute to its efficacy since it has been demonstrated that selective inhibition of EGFR with gefitinib did not yield clinical responses in MTC [7]. Here, EGFR is linked to medullary thyroid gland carcinoma.